FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS

Background:Cardiovascular (CV) comorbidities are common in psoriatic arthritis (PsA); patients are at high risk for major adverse cardiovascular events (MACE).1In the Phase 2, double-blind, randomized EQUATOR trial, significant improvements across multiple PsA domains were observed with the oral selective Janus kinase (JAK) 1 inhibitor filgotinib compared with placebo.2Inhibition of JAK signal transducer and activator of transcription signaling is associated with raised serum lipids.3Objectives:To evaluate the effects of filgotinib on the lipid profile of PsA patients and determine if those with higher MACE risk show similar changes in lipid profile compared with the overall population.Methods:In EQUATOR, 131 patients with active PsA received filgotinib 200 mg (n=65) or placebo (n=66) once daily for 16 weeks. Patients completing EQUATOR could enter the ongoing EQUATOR2 open-label extension (OLE;NCT03320876), in which patients receive filgotinib 200 mg for up to 148 weeks. Effects of filgotinib on total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and TC/HDL-C ratio at OLE Week 52 (68 weeks after EQUATOR initiation) were analyzed. In a post hoc analysis, patients were classified into subgroups according to presence/absence of obesity (baseline body mass index [BMI]; ≥30 vs <30 kg/m2, respectively), diabetes mellitus, arterial hypertension (≥130/80 mmHg), hyperlipidemia, and metabolic syndrome. Changes in lipid levels were explored graphically.Results:124 patients (95%) completed EQUATOR; 122 (93%) enrolled in the OLE. Of these, 11 patients (9%) discontinued treatment by OLE Week 52. Median (range) exposure to filgotinib was 66.0 (0.4–104.1) weeks. In the OLE, TC, LDL-C, and HDL-C levels increased versus baseline with filgotinib, resulting in a decreased TC/HDL-C ratio. Changes in lipid levels were consistent irrespective of presence of obesity (n=56;Fig), diabetes (n=53), arterial hypertension (n=80), hyperlipidemia (n=108), or metabolic syndrome (n=36); baseline lipid values were greater in the higher risk groups. In patients who were assigned placebo in the randomized controlled trial (RCT), HDL-C increased on switching to filgotinib in the OLE (in a manner similar to that seen in filgotinib-treated patients during the RCT), and remained elevated compared with baseline (Fig). Triglyceride levels remained stable throughout, across all subgroups. Seventeen patients (13%) were taking lipid-lowering drugs (LLDs) prior to the start of the trial (and continued to do so); the effect of filgotinib on the lipid profile in these patients was similar to that in the overall population. During the RCT phase, another six patients in the filgotinib group and one in the placebo group began taking LLDs.Conclusion:In patients exposed to filgotinib for ≥52 weeks, the effects on lipid profile were consistent regardless of baseline CV risk. Lipid changes included an elevation in TC and HDL-C, with a decrease in TC/HDL-C ratio.References:[1]Haddad A & Zisman D. Rambam Maimonides Med J 2017;8:e0004[2]Mease P, et al. Lancet 2018;392:2367–77[3]Sands B, et al. Clin Gastroenterol Hepatol 2020;18:123–32Acknowledgments:Studies were sponsored by Galapagos NV; co-funded by Galapagos NV and Gilead Sciences. Writing support from Hannah Mace MPharmacol, CMPP (Aspire Scientific Ltd, Bollington, UK) was funded by Galapagos NV (Mechelen, Belgium).Disclosure of Interests:M Elaine Husni Grant/research support from: Pfizer, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Regeneron, and UCB, Dafna D Gladman Grant/research support from: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – grant/research support, Consultant of: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – consultant, Philip Helliwell: None declared, Filip van den Bosch Consultant of: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Chantal Tasset Shareholder of: Galapagos (share/warrant holder), Employee of: Galapagos, Luc Meuleners Employee of: Galapagos, Leen Gilles Consultant of: Galapagos, Lien Gheyle Employee of: Galapagos, Mona Trivedi Shareholder of: Amgen and Gilead Sciences, Employee of: Gilead Sciences, Muhsen Alani Employee of: Gilead Sciences, Robin Besuyen Shareholder of: Galapagos, Employee of: Galapagos, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau

Download Full-text

Effect of Red Raspberry (Rubus idaeus L.) Consumption With or Without Fructo-Oligosaccharide on Metabolic Indices: A Single-Blinded Randomized, Crossover Clinical Trial (OR29-03-19)

Current Developments in Nutrition ◽

10.1093/cdn/nzz031.or29-03-19 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

Author(s):

Xuhuiqun Zhang ◽

Anqi Zhao ◽

Indika Edirisinghe ◽

Amandeep Sandhu ◽

Britt Burton-Freeman

Keyword(s):

Clinical Trial ◽

Lipid Profile ◽

Plasma Lipid ◽

Density Lipoprotein ◽

Rubus Idaeus ◽

Lipoprotein Cholesterol ◽

Lipid Lowering ◽

Lowering Effect ◽

Insulin Responses ◽

Lipid Lowering Effect

Abstract Objectives Red raspberries (RRB) contain a unique polyphenol profile associated with cardio-metabolic benefits. Fructo-oligosaccharides (FOS), as prebiotics, present an approach to augment the cardio-metabolic benefits of RRB through their known effects in modifying the gut microbiota composition. The objective of this study is to determine the effect of RRB intake with or without FOS on glucose and insulin responses and fasting lipid profile in insulin-resistant (IR) (n = 20) and metabolically healthy reference (R) adults (n = 11) in a single-blinded, randomized, 12-week crossover clinical trial. Methods In this crossover study, after one-week run-in, subjects consumed RRB (1 cup RRB equivalence) or RRB + FOS (1 cup RRB equivalence with 8 g FOS) for 4 weeks in random order separated by 4-week washout between supplementation periods. Before and after each supplementation period, glucose and insulin responses were assessed by 2-h postprandial glycemic challenge with RRB (75 g glucose equivalence) and the plasma lipid profile characterized (total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and triglycerides (TG)). Results IR group had significantly elevated fasting and postprandial glucose and insulin, and higher fasting TG and lower HDL compared to R at baseline (0-week) (P ≤ 0.05); no differences in TC and LDL between groups (P > 0.05). After 4-week intervention, RRB decreased TC and LDL of IR group from baseline by 7% (P = 0.024) and 9% (P = 0.007), respectively, whereas adding FOS significantly attenuated the lipid-lowering effect of RRB. Alternatively, addingFOS to RRB augmented RRB effect on glycemic variables: 4-week intake of RRB + FOS significantly decreased 30 min incremental areas under curve (iAUC 0–30) of IR group for glucose and insulin from baseline by 20% (P = 0.014) and 18% (P = 0.012), respectively. Conclusions 4-week RRB intervention improves glycemic and lipid profiles in people with IR. Adding FOS to RRB supplement enhanced the glycemic benefits, but attenuated the lipid-lowering effect of RRB. Funding Sources This work was supported by the National Processed Raspberry Council.

Download Full-text

Effect of Cholecystectomy on Serum Lipids and Blood Glucose (Hospital Based Observational Prospective Study)

Nepal Journal of Medical Sciences ◽

10.3126/njms.v6i1.36725 ◽

2021 ◽

Vol 6 (1) ◽

pp. 8-13

Author(s):

Om Karki ◽

Bishow Deep Timilsina

Keyword(s):

Blood Glucose ◽

Blood Glucose Level ◽

Lipid Profile ◽

Glucose Level ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Atherogenic Index ◽

Lipid Lowering ◽

Lowering Drug

Introduction: Association between cholelithiasis and dyslipidemia has been shown in many studies. Recent studies have shown improvement in lipid profile following cholecystectomy. This study aimed to determine the changes in lipid profile and blood glucose level after cholecystectomy.Methods: Seventy-three patients of cholelithiasis were studied prospectively. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), atherogenic index (AI) and fasting blood sugar (FBS) levels were estimated pre-operatively. Further, the same parameters were studied after cholecystectomy after one week and one-month intervals. None of the patients received any lipid-lowering drug or dietary restriction. Results were analysed and compared.Results: Of the 73 patients with cholelithiasis, 66% were female and 34% male. The mean age of patients was 40.53± 13.16 years. 56% of patients with cholelithiasis had a deranged lipid profile. TC was significantly decreased at one week (p=0.002) and one month (p=0.00) interval after cholecystectomy while TG levels also decreased significantly at one month postoperative (p=0.001). There were no significant differences in LDL-c however improvement was seen on HDL-c. Blood glucose level also increased significantly (p=0.028) after one month of cholecystectomy.Conclusion: Cholelithiasis is associated with an abnormal lipid profile. Cholecystectomy leads to a significant decrease in some of the parameters of lipid profile and the atherogenic index. The presence of gall stones thus should be perceived in the context of metabolic syndrome, which may be investigated and treated.

Download Full-text

Are maternal metabolic syndrome and lipid profile associated with preterm delivery and preterm premature rupture of membranes?

10.21203/rs.2.15292/v1 ◽

2019 ◽

Author(s):

Lida Moghaddam-Banaem ◽

Shiva Niyaty ◽

Hadis Sourinejad ◽

Samira Mokhlesi

Keyword(s):

Metabolic Syndrome ◽

Lipid Profile ◽

Preterm Delivery ◽

Challenge Test ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

P Value ◽

Premature Rupture Of Membranes ◽

Premature Rupture ◽

Preterm Premature Rupture

Abstract Objectives We aimed to evaluate the association of metabolic syndrome (MetS), its components and lipid profile in mid-pregnancy with preterm delivery and preterm premature rupture of membranes (PPROM).Methods This prospective cohort study was conducted on 203 pregnant women between 24-28 weeks of gestation, undergoing the gestational diabetes screening test with 50 gr glucose challenge test (GCT). Fasting serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), high -density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels were measured during the week after GCT assessment. Information on the participants' pre-pregnancy weight, demographic/ reproductive characteristics, and height and blood pressure (BP) measurements were documented at baseline entry into the study. Metabolic syndrome was defined as the co-existence of 3 or more of the following criteria: Body mass index (BMI) before pregnancy≥30 kg/m2, BP≥130/85 mmHg, GCT≥140mg/dl, TG≥150mg/dl, and HDL-C≤50mg/dl. All participants were followed through routine prenatal care, up to delivery. Any deliveries or rupture of membranes of less than or equal to weeks of pregnancy, were considered preterm delivery and PPROM respectively. Statistical analysis was performed by SPSS V.20, and p-value of less than 0.05 was considered significant.Results MetS was detected in 10 (4.9%) of participants. Logistic regression analysis showed HDL-C levels, and hypertension had significant effects on preterm delivery occurrence [(OR: 0.952, 95%CI: 0.910_0.995), (OR: 1.629, 95% CI: 1.554_1.709) respectively], but no statistically significant results were found for PPROM.Conclusions Low HDL-C levels and hypertension in mid-pregnancy may increase the occurrence of preterm deliveries, indicating that MetS and its components should be monitored more closely in pregnancy.

Download Full-text

P1884Low lipid levels and high variability correlate with the risk of new-onset atrial fibrillation

European Heart Journal ◽

10.1093/eurheartj/ehz748.0632 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

H Lee ◽

S R Lee ◽

E K Choi ◽

K D Han ◽

S Oh

Keyword(s):

Atrial Fibrillation ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Population Based ◽

Lipoprotein Cholesterol ◽

Lipid Lowering ◽

Atherosclerotic Cardiovascular Disease ◽

Lipid Levels ◽

Lipid Parameter ◽

Bottom Quartile

Abstract Background High levels of lipids and lipid variability are established risk factors for atherosclerotic cardiovascular disease. We investigated their roles in the development of atrial fibrillation (AF). This is the largest cohort study yet on the association between lipid levels and AF, and the first study on the association between lipid variability and AF. Methods A nationwide population-based cohort of 3,828,652 adults (mean age 43.9 years) from the Korean National Health Insurance Service database without prevalent AF, not on lipid-lowering medication, and with at least 3 measurements of each lipid parameter at 1–2 year intervals over a 4-year period were included. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were measured, and lipid variability was calculated using variability independent of mean. The cohort was divided into quartiles by baseline lipid levels and lipid variability, and followed up for incident AF. Results During median 3.4 years of follow-up, AF was newly diagnosed in 13,240 (0.35%). AF development was inversely associated with TC and LDL-C levels (for top vs. bottom quartile; TC, hazard ratio [HR] 0.76, 95% confidence interval [95% CI] 0.72–0.80); LDL-C, HR 0.78, 95% CI 0.74–0.82) in both sexes, and with TG levels in men (HR 0.85, 95% CI 0.80–0.90). Meanwhile, AF development was associated with higher LDL-C and HDL-C variability (for top vs. bottom quartile; LDL-C, HR 1.16, 95% CI 1.10–1.22; HDL-C, HR 1.08, 95% CI 1.03–1.14) in both sexes, and with TC variability in men (HR 1.16, 95% CI 1.10–1.22). Conclusions Lower cholesterol levels (TC, LDL-C) and higher cholesterol variability (LDL-C, HDL-C) were associated with higher risk for AF. Low TG levels and high TC variability were also associated with AF incidence in men. These findings support the “cholesterol paradox” in AF, and suggest that cholesterol variability is also a risk factor for AF development.

Download Full-text

Investigation of ischemia modified albumin and coenzyme Q10 levels in obese children with metabolic syndrome

Turkish Journal of Biochemistry ◽

10.1515/tjb-2016-0147 ◽

2016 ◽

Vol 41 (6) ◽

Cited By ~ 1

Author(s):

Sabahattin Muhtaroğlu ◽

Selda Özkan Koçak ◽

İhsan Çetin ◽

Didem Barlak Keti ◽

Mustafa Kendirci

Keyword(s):

Metabolic Syndrome ◽

Lipid Profile ◽

Low Density Lipoprotein ◽

Colorimetric Method ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Healthy Children ◽

Model Assessment ◽

Obese Children ◽

Ischemia Modified Albumin

AbstractIntroduction:The aim of this study was to analyze serum ischemia modified albumin (IMA) and plasma CoQ10 levels and to evaluate their correlation with insulin resistance (homeostatic model assessment, HOMA) and lipid profile in obese children with and without metabolic syndrome (MS).Methods:Thirty-one obese with MS, 30 obese without MS and 34 healthy children aged 6–18 years were included in the study. Serum IMA was measured by colorimetric method, plasma CoQ10 levels were measured by HPLC. Serum glucose, total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol and insulin were analyzed.Results:IMA levels were found to be significantly higher (p<0.001) while the CoQ10 levels were significantly lower (p<0.001) in obese children with and without MS compared to controls. IMA and CoQ10 significantly correlated with each other and metabolic parameters. Furthermore, IMA and CoQ10 levels did not significantly differ between obese children with and without MS, while glucose, insulin levels and HOMA were significantly higher (p<0.001) in obese children with MS than obese without MS and controls.Conclusions:Based on the high levels of IMA, low CoQ10 and association with HOMA and lipid profile; we suggest that obese children may have oxidative damage, lipid peroxidation and cardiometabolic risk.

Download Full-text

Long-Term Burden of Increased Body Mass Index from Childhood on Adult Dyslipidemia: The i3C Consortium Study

Journal of Clinical Medicine ◽

10.3390/jcm8101725 ◽

2019 ◽

Vol 8 (10) ◽

pp. 1725 ◽

Cited By ~ 1

Author(s):

Yinkun Yan ◽

Lydia A. Bazzano ◽

Markus Juonala ◽

Olli T. Raitakari ◽

Jorma S. A. Viikari ◽

...

Keyword(s):

Body Mass Index ◽

Body Mass ◽

Early Life ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Lipid Lowering ◽

Lipid Levels ◽

Increased Risk ◽

The Impact

Background: Data are limited regarding the association of cumulative burden and trajectory of body mass index (BMI) from early life with adult lipid disorders. Methods: The study cohort consisted of 5195 adults who had BMI repeatedly measured 4 to 21 times from childhood and had blood lipid measurements of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) and information on lipid-lowering medications in the last adult survey. The area under the curve (AUC) was calculated as a measure of long-term burden (total AUC) and trends (incremental AUC) of BMI. Results: Participants with dyslipidemia, high LDL-C, low HDL-C and high TG had consistently and significantly higher BMI levels from childhood to adulthood compared to those with normal lipid levels. After adjusting for age, race, sex, and cohort, increased risk of adult dyslipidemia was significantly associated with higher values of childhood BMI, adulthood BMI, total AUC and incremental AUC, with odds ratio (95% confidence interval) = 1.22 (1.15–1.29), 1.85 (1.74–1.97), 1.61 (1.52–1.71), and 1.59 (1.50–1.69), respectively, and p < 0.001 for all. The association patterns were similar in most race–sex subgroups. Conclusions: Adults with dyslipidemia versus normal lipid levels have consistently higher levels and distinct life-course trajectories of BMI, suggesting that the impact of excessive body weight on dyslipidemia originates in early life.

Download Full-text

AB1225 LIPID PROFILE COMPARISON IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: A CASE-CONTROL STUDY

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.5805 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1904.2-1904

Author(s):

D. Á. Galarza-Delgado ◽

J. R. Azpiri-López ◽

I. J. Colunga-Pedraza ◽

A. Pérez Villar ◽

I. C. Zárate Salinas ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Psoriatic Arthritis ◽

Lipid Profile ◽

Serum Lipid ◽

Density Lipoprotein ◽

Classification Criteria ◽

Lipoprotein Cholesterol ◽

Atherogenic Index ◽

Post Hoc Analysis ◽

Post Hoc

Background:Rheumatoid arthritis (RA) and psoriasic arthritis (PsA) are autoimmune diseases, in both diseases it has been described that the main cause of morbidity and mortality is cardiovascular (CV) disease. Dyslipidemia is the most recognized CV risk factor. An association is recognized between the concentrations of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total triglycerides (TG), atherogenic index (AI) and the risk of myocardial infarction (MI), stroke and fatal cardiovascular disease (CVD). The relationship between serum lipid levels and CVD risk is potentially paradoxical in RA but this relationship has not been clarified in PsA.Objectives:To compare lipid profile between groups with RA, PsA and controls.Methods:A cross-sectional observational study was designed, which included 95 patients between 45-75 years who fulfilled the CASPAR classification criteria for PsA. 95 patients between 45-75 years who fulfilled the ACR / EULAR 2010 classification criteria for RA and 95 age-matched controls. Concentrations of CT, HDL-C, LDL-C, TG and atherogenic index were compared between the groups. Clinical measures were compared using one-way ANOVA or Kruskall-Wallis tests. Post-hoc analysis was performed with Bonferroni’s correction. Ap≤ 0.05 was considered statistically significant. The data was analyzed using the SPSS version 25 software package.Results:In our study, no significant difference in LDL-C was found between RA and PsA, however post-hoc analysis was performed where we found higher LDL-C levels among RA patients compared with controls (p0.025). RA patients had higher HDL-C than PsA patients (p0.006) but PsA had a higher HDL-C than controls (p0.007). TC/HDL-C was higher in PsA than RA and controls (p0.050). PsA patients were the group with the lowest HDL-C levels (p0.007). In contrast RA were the groups with the highest HDL-C levels (p0.007). (Table 1).Table 1.Clinical parameters.PARAMETERRAPsAControlspTC*176.6 ± 37.2176.3 ± 35.9186.34 ± 33.1720.089TG**132.7 (102.0-187.3)131.0 (97.2-189.2)118.35(88.2-162.25)0.245HDL-C**50.7 (42.1-62.6)46.7 (37.4-53.9)51.7 (41.3-60)0.007LDL-C*94.36 ± 21.7097.71 ± 30.12105.32 ±31.350.025TC/HDL-C**3.41 (2.81-4.08)3.74 (3.17-4.47)3.49 (2.99-4.52)0.050*Data are reported in mean ± SD**Data is reported in median (IQR)Conclusion:Patients with inflammatory joint diseases have more adverse lipid profiles than controls.References:[1]Pietrzak, A., Chabros, P., Grywalska, E., Kiciński, P., Pietrzak-Franciszkiewicz, K., Krasowska, D., & Kandzierski, G. (2019). Serum lipid metabolism in psoriasis and psoriatic arthritis–an update. Archives of medical science: AMS, 15(2), 369.Disclosure of Interests:None declared

Download Full-text

A COMPARATIVE STUDY OF LIPID PROFILE AND LEPTIN RESISTANCE IN CHILDREN WITH METABOLIC SYNDROME DEPENDING ON HYPERTENSION IN KYIV

Wiadomości Lekarskie ◽

10.36740/wlek202110220 ◽

2021 ◽

Vol 74 (10) ◽

pp. 2630-2633

Author(s):

Maiia H. Aliusef ◽

Alina V. Churylina ◽

Ganna V. Gnyloskurenko ◽

Inga O. Mitiuriaeva ◽

Vitaliy G. Maidannyk

Keyword(s):

Blood Pressure ◽

Metabolic Syndrome ◽

High Density Lipoprotein ◽

Lipid Profile ◽

High Density Lipoprotein Cholesterol ◽

Density Lipoprotein ◽

High Density ◽

Lipoprotein Cholesterol ◽

Leptin Resistance ◽

Normal Blood Pressure

The aim: To compare lipid metabolism and leptin levels among the children with and without hypertension to identify associated risk factors for the course of metabolic syndrome in children. Materials and methods: This observational, cross-sectional study recruited children from the Rheumocardiology Department of Children’s Clinical Hospital No 6 in Kyiv, with metabolic syndrome, identification of waist-to-height ratio, leptin level, homeostasis model assessment of insulin resistance and lipid profile. The main group included 41 children with metabolic syndrome and hypertension and the control group included 40 children with metabolic syndrome without hypertension. Statistical data analysis was performed using the MedStat 2.6.2. package. Results: A total of 81 children aged 10 to 17 with metabolic syndrome were examined. The group of children with hypertension had significantly lower high-density lipoprotein cholesterol (0.85±0.04) than children without hypertension (0.94±0.03), with p < 0.05. Leptin resistance was detected in 65.2% of children with hypertension and 35.3% of children with normal blood pressure (p < 0.01). Conclusions: Children with metabolic syndrome and hypertension had a significantly higher body mass index and waist circumference as opposed to children with normal blood pressure. In the lipid profile high-density lipoprotein cholesterol was significantly lower in hypertensive children. There was no reliable difference in other lipid profile indicators between the two groups, but there was an upward trend of them in group with hypertension. Leptin resistance is also significantly higher in hypertensive children.

Download Full-text

Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy

Bioscience Reports ◽

10.1042/bsr20171058 ◽

2018 ◽

Vol 38 (1) ◽

Cited By ~ 8

Author(s):

Qing-Hui Zhang ◽

Rui-Xing Yin ◽

Wu-Xian Chen ◽

Xiao-Li Cao ◽

Yu-Ming Chen

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Ischemic Stroke ◽

Serum Lipid ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Lipid Lowering ◽

Lipid Levels ◽

Serum Lipid Levels ◽

Increased Risk

Little is known about the association of the TIMD4 (T-cell immunoglobulin and mucin domain 4 gene)-HAVCR1 (hepatitis A virus cellular receptor 1) variants and lipid metabolism, the risk of coronary heart disease (CHD) and ischemic stroke (IS). The present study aimed to determine the TIMD4-HAVCR1 variants, their haplotypes and gene–environment interactions on serum lipid levels, the risk of CHD and IS, and the lipid-lowering efficacy of atorvastatin in a southern Chinese Han population. Genotypes of three variants in 622 controls, 579 CHD, and 546 IS patients were determined by the Snapshot technology. Atorvastatin calcium tablet (20 mg/day) was given in 724 hyperlipidemic patients for 8 weeks after genotyping. The rs12522248 genotypic and allelic frequencies were different between controls and patients, and were associated with the risk of CHD and IS. The rs1501908G-rs12522248T-rs2036402T haplotype was associated with an increased risk of CHD; the G-C-T haplotype was associated with lower risk of CHD; and the C-C-C haplotype was associated with an increased risk of IS. Variants and their haplotypes in controls were associated with triglyceride (rs1501908), low-density lipoprotein cholesterol (LDL-C, rs1501908, G-T-T), high-density lipoprotein cholesterol (HDL-C, rs12522248, C-C-C) and the ratio of total cholesterol (TC) to HDL-C (C-C-C). Interactions of rs1501908- and rs2036402-alcohol (HDL-C); rs1501908- and rs12522248-high body mass index (hBMI, ≥24 kg/m2; TC); and TIMD4-HAVCR1 variants-atorvastatin on several lipid parameters were detected. Interactions of rs12522248TC/CC-hBMI, G-T-T-, and C-C-C-smoking on the risk of CHD; and C-C-C-smoking, C-C-C-, and G-C-T-hBMI on the risk of IS were also observed. These findings suggest that the TIMD4-HAVCR1 variants may be the genetic risk factors for CHD and IS.

Download Full-text

Lipid Profile in Patients with Asthma and Allergic Rhinitis

International Journal of Medical Sciences ◽

10.32441/ijms.v1i2.68 ◽

2018 ◽

Vol 1 (2) ◽

pp. 9-24

Author(s):

Adnan Alwan ◽

Amina Alobaidi

Keyword(s):

Metabolic Syndrome ◽

Allergic Rhinitis ◽

Lipid Profile ◽

Pulmonary Function Tests ◽

Density Lipoprotein ◽

Normal Weight ◽

Lipoprotein Cholesterol ◽

P Value ◽

Control Subjects ◽

Significant Difference

Background: Asthma is a chronic inflammatory disease of the respiratory airways; its prevalence has increased worldwide. The disease may be associated with metabolic changes that could be either induced by treatment or may be due to inflammatory process. Aim: To clarify the status of lipid profile in Iraqi patients with asthma and allergic rhinitis. Patients and Methods: The study was performed on asthmatic patients (190), allergic rhinitis patients (110) and healthy control subjects (48). Age of subjects included were from 16-60 year, with a mean of 34.34 ±11.58 . At time of study inclusion, they all underwent full clinical examination after full history taking, pulmonary function tests, measuring body mass index and blood sampling. Results: Serum cholesterol was significantly higher in asthmatic with over weight (mean 219.93±60.02 mg/dl, P< 0.001), asthmatic with metabolic syndrome (mean 290.08±90.95 mg/dl, P<0.001), allergic rhinitis with overweight patients (mean 233.69±81.59mg/dl P< 0.001) than in control subjects (mean 145.95±36.52 mg/dl). It was of no significant difference in asthma with normal weight patients (mean 139.09±50.36 mg/dl, P-value 0.4291) and allergic rhinitis with normal weight patients (mean 155.81±49 mg/dl, P-value 0.2610) than in control subjects. Serum triglycerides was significantly higher in asthma with normal weight patients (mean 109.65±33.75 mg/dl, P-value 0.0123), asthma with over weight (mean 184.02±60.11 mg/dl, P<0.001), asthma with metabolic syndrome (mean 222.82±65.12 mg/dl, P<0.001) and allergic rhinitis with overweight patients (mean 173.62±54.27 mg/dl, P<0.001) than of control subjects (mean 92.63±35.37 mg/dl). It was of no significant difference in allergic rhinitis with normal weight patients (mean 101.56±36.29 mg/dl, P-value 0.2340) than of control subjects. High density lipoprotein-cholesterol was significantly lower in asthma with overweight group (mean 33.32±4.82 mg/dl, P<0.001), asthma with metabolic syndrome (mean 36.03±3.51 mg/dl, P<0.001), allergic rhinitis with over weight (mean 35.82±4.84mg/dl, P<0.001) than in control healthy group (mean 40.28±6.05mg/dl). It was of no significant difference between asthma with normal weight patients (mean 42.92±10.56 mg/dl, P-value 0.1215), allergic rhinitis with normal weight (mean 41.45±4.44 mg/dl, P-value 0.2600) than control subjects. Low density lipoprotein-cholesterol was significantly higher in asthma with over weight (mean 151.31±63.53 mg/dl. P<0.001); asthma with metabolic syndrome (mean 181.15±88.27 mg/dl, P<0.001); allergic rhinitis with normal weight (mean 108.42±38.05 mg/dl, P<0.01); allergic rhinitis with over weight (mean 163.49±80.92 mg/dl, P<0.001). It was significantly lower in asthma with normal weight patients (mean 68.76±32.66 mg/dl. P<0.05) than in control subjects (mean 85.84±39.39 mg/dl). Conclusion: Asthma and / or allergic rhinitis in Iraqi population were associated with dyslipidemia, whether in the presence of metabolic syndrome, or the patients were with normal or abnormal weight.

Download Full-text